Eculizumab and Soliris
Type of Spiritual Experience
Paroxysmal nocturnal hemoglobinuria (PNH), previously Marchiafava–Micheli syndrome, is a rare, life-threatening disease of the blood characterized by destruction of red blood cells
A description of the experience
Eculizumab ( trade name Soliris) is a humanized monoclonal antibody that is a terminal complement inhibitor. In people with paroxysmal nocturnal hemoglobinuria (PNH) it improves quality of life but does not appear to affect the risk of death. Its safety is unclear as of 2014. It is the first approved therapy for paroxysmal nocturnal hemoglobinuria. Eculizumab is also the first agent approved treatment of atypical hemolytic uremic syndrome (aHUS) with likely benefit based on two small trials.
Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007 for the treatment of PNH, and on September 23, 2011 for the treatment of aHUS. It was approved by the European Medicines Agency for the treatment of PNH on June 20, 2007, and on November 24, 2011 for the treatment of aHUS. Eculizumab is currently being investigated as a potential treatment for other rare disorders. Eculizumab has exclusivity rights until 2017 which protects it from competition from biosimilar applications until 2017.
Soliris is considered to be the most expensive drug in the world. It costs £340,200 (approximately €430,000) per year for ongoing treatment in the UK and $500,000 a year in Canada and USD$409,500 a year in the United States (2010).
"Before testing Soliris for PNH, Alexion tested the drug for rheumatoid arthritis. The trials failed.
On Jan, 05, 2017 23,225 people reported to have side effects when taking Soliris.
Among them, 17 people (0.07%) have Hallucination
Time on Soliris when people have Hallucination :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Gender of people who have Hallucination when taking Soliris :
Age of people who have Hallucination when taking Soliris :